Core Insights - Viemed Healthcare is focused on home-based respiratory care, emphasizing a model that reduces hospital visits and readmissions while managing complex respiratory patients [3][4][20] Financial Performance - In 2025, Viemed reported over $270 million in revenue and $28 million in free cash flow, maintaining a net debt-free status [2][14] - The company has guided for 2026 revenue between $310 million and $320 million, with EBITDA projected at $65 million to $69 million [16] - Viemed has achieved a 26% compound annual growth rate (CAGR) since going public, with over 172,000 patients under care [2][7] Market Opportunity - There are approximately 1.25 million Medicare candidates for complex respiratory care, with only about 70,000 currently treated, indicating a penetration rate of roughly 6% [5][7] - The U.S. has around 25 million people with Chronic Obstructive Pulmonary Disease (COPD), with about 2.5 million at the most severe level, representing a significant market opportunity for Viemed [7] Service Diversification - Viemed has diversified its service offerings, with ventilation revenue decreasing from 87% in 2019 to 48% today, while sleep services now account for 21% of net revenue [6][11] - The company has expanded into maternal health, staffing, and other respiratory services, with a notable 62% growth in CPAP patients in 2025 [10][12] Regulatory Environment - Management highlighted supportive regulatory changes, including a new ventilator National Coverage Determination (NCD) that clarifies coverage requirements and reduces reimbursement uncertainty [21][20] - Recent reimbursement trends have been linked to Consumer Price Index (CPI) increases, with expectations for further adjustments in the coming years [22] Technology and Operational Model - Viemed employs in-house technology for remote patient monitoring and telehealth interactions, which has shown to reduce emergency room visits and hospitalizations [8][9] - The company's operating model is lean and scalable, relying on a mobile workforce rather than traditional retail locations [9]

AdaptHealth Conference Call Summary Company Overview - **Company**: AdaptHealth (NasdaqCM: AHCO) - **Industry**: Sleep Apnea and Respiratory Equipment Key Points Sleep Apnea Market Insights - Approximately **33-34 million Americans** suffer from obstructive sleep apnea (OSA), with only **20%** diagnosed and treated, indicating a significant underdiagnosed population [2][38] - The market is expected to grow at a rate of **low to mid-single digits** annually [40] - AdaptHealth holds about **25%** of the U.S. CPAP market, significantly larger than any competitor [41] Patient Adherence and Revenue Model - AdaptHealth reports an adherence rate of over **80%**, compared to the industry average of just over **70%** [9][7] - The company receives approximately **$60 per month** from Medicare for CPAP rentals over a **13-month** period, with an average resupply order costing about **$200** [25][11] - Patients are typically resupplied just under **three times a year**, compared to the industry average of **two times** [11] Operational Efficiency - The average setup time for patients has improved from **17 days** to **9 days**, enhancing patient satisfaction and referral rates [35] - AdaptHealth employs **700 sales representatives** to maintain relationships with referring physicians, ensuring a steady flow of patient referrals [33] Growth Strategies - The company is expanding its presence on the **West Coast** with **30 new locations** and an acquisition in Hawaii, aiming to capture more market share in previously underserved areas [42][43] - AdaptHealth is actively pursuing additional capitated contracts, with a dedicated team working on pricing and competitive bids [114] Regulatory Environment - The **CMS** has increased the fee schedule by just over **2%** for 2026, which is beneficial for the industry [105] - The **SOAR Act** is being lobbied to increase reimbursement levels for respiratory services, which is a significant category for AdaptHealth [109] Competitive Landscape - AdaptHealth has not seen any impact from competitors claiming preferred status with payers, maintaining stable referral patterns [95][96] - The company views competitive bidding as an opportunity for consolidation and market share growth, especially in the CGM distribution segment [91][92] Financial Performance - Adjusted EBITDA margins for sleep and respiratory segments run in the **high 20%** range, with gross margins around **60%** for resupply costs [118][119] Challenges and Opportunities - The transition of patients from incumbent providers is complex, but AdaptHealth is leveraging lessons learned from previous contracts to streamline this process [68] - The company is focused on enhancing its core offerings rather than diversifying into new product lines, given the significant growth potential within existing markets [113] Additional Insights - AdaptHealth's proactive approach to patient adherence and operational efficiency positions it well for future growth in the sleep apnea and respiratory equipment markets [6][20] - The company is committed to maintaining high patient satisfaction to ensure continued referrals from healthcare providers [34][122]

Financial Data and Key Metrics Changes - The company reported a headline revenue growth of 11% for Q2 FY2026, with a 9% increase on a constant currency basis, resulting in total revenue of $1.42 billion [7][61] - GAAP EPS grew by 16%, reflecting strong double-digit bottom line growth [8] - Gross margin increased by 110 basis points year-over-year to 62.3%, driven by component cost improvements and manufacturing efficiencies [66] - Operating profits rose by 19%, with an operating margin improvement to 36.3% compared to 34% in the prior year [72] Business Line Data and Key Metrics Changes - Global devices revenue experienced high single-digit growth, while masks, accessories, and other revenue saw double-digit growth [9] - Device sales increased by 7% globally on a constant currency basis, while masks and other sales increased by 14% [61] - The Residential Care Software business revenue grew by 5% on a constant currency basis, supported by strong performance from the MEDIFOX DAN software vertical [64] Market Data and Key Metrics Changes - Sales in the U.S., Canada, and Latin America increased by 11%, with a 6% increase on a constant currency basis [62] - In Europe, Asia, and other regions, device sales increased by 5% and masks and other sales increased by 8% on a constant currency basis [64] Company Strategy and Development Direction - The company aims to build a leading digital health ecosystem encompassing sleep health, breathing health, and healthcare technology delivered in the home [15] - ResMed is focused on operational excellence and innovation, with a commitment to maintaining strong free cash flow and a robust balance sheet to support investments and shareholder returns [16][45] - The company is expanding its mask portfolio and enhancing its digital health capabilities, including AI-driven solutions to improve patient adherence to therapy [20][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate global macro uncertainties and highlighted the positive impact of GLP-1 medications on patient engagement and therapy adherence [41][90] - The company is closely monitoring the global trade environment and regulatory landscape, with expectations of continued growth in the sleep health market [42][43] Other Important Information - The company declared a quarterly dividend of $0.60 per share and plans to repurchase shares totaling more than $600 million for FY2026 [76][53] - ResMed's cash balance at the end of Q2 was $1.4 billion, with a solid liquidity position and strong operating cash flows [75] Q&A Session Summary Question: Strong U.S. mask number - Management noted that the strong growth in masks includes contributions from the VirtuOx acquisition, but even without it, there was still double-digit growth in masks and accessories [81][85] Question: Update on GLP-1 landscape - Management confirmed that patients on GLP-1 therapy show a higher motivation to start and adhere to CPAP therapy, with a 10%-11% higher start rate observed [89][92] Question: SG&A growth ahead of revenue growth - Management indicated that the SG&A growth was influenced by the VirtuOx acquisition and marketing programs, but underlying growth was tracking closely with revenue [97] Question: Impact on patient funnel - Management highlighted that the top of the funnel has seen significant progress due to increased awareness from big pharma and tech, and they are focused on scaling home sleep apnea testing [100][102] Question: Philips' potential return to the U.S. market - Management stated uncertainty regarding Philips' re-entry timing and emphasized their focus on current market dynamics and patient flow [128][130]

Financial Data and Key Metrics Changes - ResMed reported an 11% headline revenue growth for Q2 FY2026, with a 9% increase on a constant currency basis, achieving GAAP EPS growth of 16% [7][8][55] - Gross margin increased by 110 basis points year-over-year to 62.3%, driven by component cost improvements and manufacturing efficiencies [58] - Operating profits rose by 19%, with operating margin improving to 36.3% compared to 34% in the prior year [63] Business Line Data and Key Metrics Changes - Global devices revenue grew by high single digits, while masks, accessories, and other revenue saw double-digit growth [9][55] - Residential care software revenue increased by 5% on a constant currency basis, supported by strong performance from the Medifox Dan software vertical [57] Market Data and Key Metrics Changes - In the U.S., Canada, and Latin America, sales increased by 11%, with a 6% increase on a constant currency basis [55] - In Europe, Asia, and other regions, device sales increased by 5% on a constant currency basis, while masks and other sales increased by 8% [56] Company Strategy and Development Direction - ResMed aims to expand its digital health ecosystem, focusing on sleep health and breathing health, while maintaining a strong balance sheet and free cash flow for investments and shareholder returns [14][39] - The company is investing in R&D for next-generation products and enhancing its manufacturing capabilities, including a new distribution center in Indiana [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable high single-digit growth in the residential care software business by FY2027 [11] - The management highlighted the positive impact of GLP-1 medications on patient engagement and adherence to CPAP therapy, indicating a potential tailwind for future growth [78][104] Other Important Information - ResMed returned $263 million to shareholders through dividends and share repurchases during the quarter, with plans to increase share repurchases to over $600 million for FY2026 [67][68] - The company is actively monitoring the global trade environment and regulatory landscape, with no inclusion of CPAP products in CMS's competitive bidding program [37] Q&A Session Summary Question: Strong US mask number - Management noted that the strong growth in masks includes contributions from the Virtuox acquisition, but even without it, there was still double-digit growth in masks and accessories [70][72] Question: Update on GLP-1 landscape - Management confirmed that patients on GLP-1 therapy show a higher motivation to start and adhere to CPAP therapy, with a 10%-11% higher start rate observed [78][80] Question: SG&A growth ahead of revenue growth - Management indicated that the SG&A growth was influenced by the Virtuox acquisition and marketing programs, but underlying growth was tracking closely with revenue [87] Question: Impact of GLP-1 on patient funnel - Management highlighted that GLP-1 medications are bringing more motivated patients into the healthcare system, leading to higher adherence rates for CPAP therapy [80][104] Question: Philips' potential return to the U.S. market - Management stated uncertainty regarding Philips' re-entry into the U.S. market but noted that ResMed is performing well in competing against them in other regions [114][116]

AdaptHealth Conference Call Summary Company Overview - **Company**: AdaptHealth (Ticker: AHCO) - **Industry**: Durable Medical Equipment (DME) - **Key Segments**: CPAP for obstructive sleep apnea (OSA), diabetes management, respiratory therapies, and wellness at home [2][3] Key Points and Arguments Market Position and Growth - AdaptHealth is the largest DME operator in the U.S., supplying approximately 25% of the 6-7 million patients treated for OSA [3] - The market for OSA is underpenetrated, with estimates of 33-34 million Americans affected, indicating significant growth potential [3] - In Q2 2025, AdaptHealth set up 128,000 new CPAP patients, reflecting over 3% growth year-over-year [3] Business Segment Performance - **Sleep Segment**: Expected to maintain mid-single-digit growth, potentially reaching 5% if diabetes returns to growth [4] - **Respiratory Segment**: Anticipated growth of 3-3.5%, with current performance exceeding expectations despite a softer flu season [4] - **Diabetes Segment**: After operational changes, the segment is showing improvement with record retention levels, aiming to return to growth mode [5] - **Wellness at Home**: Completed two significant dispositions in Q2, using proceeds to reduce debt [6] Financial Outlook - Top-line organic revenue growth is projected at 3-4%, with potential contributions from tuck-in M&A [7] - A significant contract with a major healthcare system is expected to generate at least $200 million annually, with adjusted EBITDA margins of 20-21% [8] - Anticipated improvements in EBITDA due to accounting changes and cost reductions from AI and automation investments [9][10] Competitive Landscape and Regulatory Environment - The DME market is expected to consolidate further, with competitive bidding reducing the number of operators [13][19] - AdaptHealth believes it is well-positioned to win contracts in the upcoming competitive bidding rounds, with a focus on service level agreements to enhance payer relationships [14][16] - The diabetes segment will face new competitive pricing dynamics, with fewer operators expected to win contracts [21][22] Innovation and Market Dynamics - Concerns exist regarding alternative therapies impacting CPAP usage, but demand for sleep apnea treatment remains strong [37][39] - The company is monitoring the impact of new technologies and wearables on patient detection and adherence [38] Cash Flow and Capital Deployment - Free cash flow generation is projected to remain between 6-7% of revenue, with ongoing debt reduction and modest M&A activities planned [44] - The company aims to achieve a leverage target of 2.5 times EBITDA by mid-2026 [43] Investor Insights - The transformation towards increased free cash flow generation is a key focus, with strategic dispositions aimed at improving financial health [48][50] - Anticipated tax benefits from equipment purchases and bonus depreciation will enhance cash flow in the coming years [50] Additional Important Points - AdaptHealth's competitive advantage lies in its scale and technology, allowing it to offer better service and pricing compared to smaller operators [15][16] - The company is committed to continuous improvement in service delivery and operational efficiency [14][15] - The management team has undergone significant changes to enhance performance in the diabetes segment, with a focus on sales and retention strategies [33][34]

ResMed Conference Call Summary Company Overview - **Company**: ResMed (NYSE:RMD) - **Industry**: Digital health and medical devices, focusing on sleep health, breathing health, and healthcare technology delivered at home - **Headquarters**: San Diego, California - **Founded**: 1989 - **Market Presence**: Sold 30 million cloud-connectable medical devices in 140 countries, with 23 billion nights of respiratory medical data collected [5][6] Core Strategies and Goals - **ResMed 2030 Strategy**: Aims to improve 500 million lives by 2030 through innovative products and services [6][7] - **Recent Achievements**: Changed 154 million lives in the last 12 months with devices and software [7] - **Product Development**: Focus on creating the smallest, quietest, and most comfortable devices, with a strong emphasis on cloud connectivity and intelligence [7][10] Financial Performance - **Free Cash Flow**: Generated over $1.7 billion in free cash flow in the last 12 months [9] - **Gross Margin Improvement**: Achieved 230 basis points year-on-year gross margin accretion in Q4 and 150 basis points quarter-on-quarter [9][10] - **Net Operating Profit Margins**: Currently in the range of 33-34% [10] Innovation and Product Development - **New Products**: Launched innovative products like the AirTouch N30i and AirFit F40, incorporating fabric into patient interfaces [11] - **Acquisitions**: Acquired Ectosense for its home sleep testing technology and Virtuox for home sleep apnea testing [12][57] - **Research Utilization**: Leveraging 23 billion nights of data to improve products and contribute to peer-reviewed research [13][14] Market Dynamics and Competitive Landscape - **Tariff Relief**: ResMed products benefit from tariff relief under the Nairobi Protocol, ensuring no tariffs on products made in various locations [12] - **Competitor Landscape**: Competitors have been affected by recalls, but ResMed remains confident in its market position and growth potential [47][48] - **Market Growth**: The device market is expected to grow mid-single digits, with ResMed aiming to exceed this through demand generation efforts [58] Patient Engagement and Adherence - **Adherence Rates**: Connected devices have increased adherence from 50% to 73%, and with app usage, adherence can reach 87% [14][20] - **GLP-1 Drug Impact**: Patients on GLP-1 weight loss drugs are 11% more likely to start CPAP therapy and show higher resupply rates [24][25] - **Patient Empowerment**: Focus on educating patients about access to equipment and the importance of adherence to therapy [20][23] Research and Development - **Investment in R&D**: ResMed invests 6-7% of revenues back into research and development to drive innovation [55] - **Future Growth**: Aiming for double-digit basis point improvements in gross margins annually through supply chain optimization and product innovation [63][64] Conclusion - ResMed is positioned as a leader in the digital health space, with a strong focus on innovation, patient engagement, and financial performance. The company is actively working to expand its market presence and improve patient outcomes through its 2030 strategy and ongoing product development initiatives.

Financial Data and Key Metrics Changes - The company reported record FRE of $323 million, an 18% increase year over year, with a FRE margin of 48% for the first half [7][22] - Total AUM reached a record $465 billion, with first half inflows totaling $28 billion and $51 billion over the last twelve months, reflecting a 12% organic growth rate [23][24] - Management fees for the quarter were $590 million, a 7% increase year to date, while capital market fees were $48 million in the second quarter, more than double from last year [22][23] Business Line Data and Key Metrics Changes - Carlyle Alpinvest experienced a record quarter with fee revenues up more than 50% and FRE nearly doubling over the past year [17] - Global Credit delivered strong performance with FRE of $111 million, a 37% year over year increase, and asset-backed finance AUM up 40% year over year [25][26] - The U.S. Buyout funds appreciated approximately 20% over the past twelve months, while the tenth vintage U.S. Real Estate fund closed at $9 billion, nearly 15% larger than its predecessor [13][27] Market Data and Key Metrics Changes - The macro environment showed improved sentiment, with equity markets near record highs and increased M&A activity due to reduced uncertainty from tariff negotiations and tax policy [9][10] - The company deployed $26 billion in 2025, up almost 50% year over year, indicating strong demand for private capital [10][11] Company Strategy and Development Direction - The company is focused on expanding its wealth management capabilities, with a partnership with UBS to provide private equity secondary solutions for their international wealth clients [20][110] - The strategic emphasis is on leveraging brand recognition and diversification of the platform to enhance growth in wealth management and private equity [111][112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting full year FRE growth of approximately 10%, up from a prior outlook of 6% [30] - The leadership transition is seen as a natural evolution to enhance operational scale and agility in executing the company's strategy [21][88] Other Important Information - The company returned nearly $15 billion to investors over the last twelve months, which is three times the industry average [11][29] - The firm is actively pursuing opportunities in the capital markets, generating over $230 million in fees over the last twelve months, with expectations for further growth as M&A and IPO activities increase [20][21] Q&A Session Summary Question: Drivers of FRE growth and future guidance - Management indicated that the revised outlook reflects strong momentum across the platform, with organic growth at Alpinvest being exceptional [41][42] Question: Retail commentary and fundraising potential - Management highlighted the systematic strategy for engaging wealth clients and the expected positive impact of the upcoming CPAP launch [52][56] Question: Outlook for the credit business - The company sees significant growth potential in the credit business, particularly in private credit and asset-based finance, driven by increasing demand for capital [66][67] Question: Near-term outlook for Alpenvest and Solutions business - Management noted that the business has evolved to generate consistent growth, with CAPM being a significant driver [73][76] Question: Capital markets fees growth and strategy - The company expects capital markets fees to continue growing, driven by organic opportunities and the scale of the platform [101][106] Question: Wealth products and future vision - Management emphasized the importance of brand recognition and diversification in driving success in wealth management [110][112]

Financial Data and Key Metrics Changes - The company reported record FRE of $323 million, an 18% increase year over year, with a FRE margin of 48% for the first half [6][19] - Total DE for the first six months was $2.5 per share, marking a record start for the firm [19] - Management fees reached $590 million for the quarter, a 7% increase year over year, while capital market fees were $48 million, more than double last year [20][19] - Firm-wide AUM ended the quarter at $465 billion, with inflows totaling $28 billion for the first half and $51 billion over the last twelve months, reflecting a 12% organic growth rate [20][6] Business Line Data and Key Metrics Changes - Global Credit and Carlyle Alpinvest delivered record FRE, together accounting for 55% of firm-wide FRE, up from less than 30% two years ago [21] - Carlyle Alpinvest FRE reached a record $68 million for the second quarter, with year-to-date FRE of $134 million, up more than 80% [21] - Global Credit FRE was $111 million for the quarter, a 37% year-over-year increase, with strong capital markets activity driving performance [22][23] - The U.S. Buyout funds appreciated approximately 20% over the past twelve months, with the tenth vintage U.S. Real Estate fund closing at $9 billion, nearly 15% larger than its predecessor [11][24] Market Data and Key Metrics Changes - The macro environment showed improved sentiment, with markets functioning well and activity accelerating, particularly in M&A and deal activity [7][8] - The company deployed $26 billion in 2025, up almost 50% year over year, indicating strong demand for private capital [8] - Asset-backed finance AUM increased by 40% year over year, reflecting significant growth in this area [14] Company Strategy and Development Direction - The company is focused on leveraging its global brand and diversified investment platform to drive growth, particularly in wealth management and capital markets [16][17] - A partnership with UBS was launched to provide private equity secondary solutions for their international wealth clients, expected to be a strong growth driver [17] - The company aims to enhance its capabilities in credit and private equity, with a focus on organic growth and strategic partnerships [58][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the firm's momentum and performance, expecting full-year FRE growth of approximately 10%, up from a prior outlook of 6% [26] - The company anticipates full-year inflows of $50 billion, compared to a previous estimate of $40 billion, indicating strong fundraising momentum [26] - Management highlighted the importance of collaboration across the Carlyle platform to drive better outcomes and performance [78] Other Important Information - The company returned nearly $15 billion to investors over the last twelve months, significantly exceeding the industry average [10][25] - Leadership appointments were announced, including John Ruddett as Co-President and Justin Bluff as the new CFO, aimed at enhancing operational scale and agility [18][26] Q&A Session All Questions and Answers Question: Drivers of FRE growth and outlook for 2026 - Management noted that the revised outlook reflects strong momentum across the platform, with organic growth at Alpinvest being exceptional [39][40] - They acknowledged the desire for longer-term guidance but emphasized the unpredictability of forecasting five years ahead [36][41] Question: Retail commentary and fundraising potential - Management discussed the systematic strategy for engaging wealth globally, highlighting the importance of brand recognition and partnerships [48][49] Question: Credit business growth outlook - Management emphasized the convergence of insurance and private credit as a significant growth opportunity, with a focus on collaborative partnerships [58][60] Question: Near-term outlook for Alpenvest and Solutions business - Management expressed confidence in consistent growth for Alpenvest, driven by new fund launches and partnerships [71][73] Question: Transition back to global private equity and collaboration - Management highlighted the strong collaborative culture within Carlyle and the exceptional performance of the corporate private equity business [78][81] Question: Net IRR of CP7 and realization performance - Management indicated that CP7 is not expected to be the best fund, but performance improvements are being made, with a focus on driving realizations [91][92] Question: Capital markets fees growth and strategy - Management discussed the strategic development of capital markets fees, emphasizing high-quality revenue streams and organic growth opportunities [98][102] Question: Wealth products and future product development - Management outlined the importance of client-centric solutions in the wealth space, with a focus on developing products that meet long-term needs [127][128]

Investment Ratings - ResMed (RMD AU) is rated Overweight (OW) with a price target of A$45.00 [24][30] - Sonic Healthcare (SHL AU) is rated Neutral (N) with a price target of A$29.00 [30][32] Core Insights - ResMed is expected to benefit from rising awareness of obstructive sleep apnoea, leading to increased demand for CPAP treatments [2][12] - Sonic Healthcare faces funding pressures that are likely to undermine its margin expansion potential [6][15] Summary by Sections ResMed - **Earnings Growth**: ResMed's earnings are projected to be approximately 5% ahead of consensus due to expected gross margin improvements and stronger revenue growth [4][12] - **Margin Expansion**: The company is on track to achieve further gross margin increases supported by production efficiency and favorable currency movements [3][24] - **Valuation**: ResMed trades at a 23x FY26E PE, which is below its historical average, indicating potential undervaluation [5][24] Sonic Healthcare - **Funding Pressures**: Sonic Healthcare is experiencing reimbursement pressures in key markets, particularly Germany and Australia, which are expected to negatively impact revenues [6][10] - **US Operations**: The US business has underperformed, and challenges are anticipated to persist in 2025 [7][9] - **Long-term Margin Decline**: Sonic's pathology margins have been in long-term decline, attributed to expansion into lower-margin markets and a tight funding environment [10][15]

Financial Data and Key Metrics Changes - First quarter revenue was $777.9 million, a decline of 1.8% from the prior year quarter, but exceeded the midpoint of guidance by $13.1 million [19][4] - Adjusted EBITDA for the first quarter was $127.9 million, down 19.3% year-over-year, with an adjusted EBITDA margin of 16.4% [5][22] - Free cash flow was negative $100,000, an improvement from negative $38.9 million in the prior year quarter [5][23] Business Line Data and Key Metrics Changes - **Sleep Health Segment**: Revenue decreased by 2.8% to $316.4 million, with new setups at approximately 113,000, slightly below expectations [20] - **Respiratory Health Segment**: Revenue increased by 3.3% to $165.5 million, driven by stronger oxygen new setups [21] - **Diabetes Health Segment**: Revenue declined by 8% to $138.8 million, but showed signs of recovery with improved new starts and the lowest attrition rate in two years [21][12] - **Wellness at Home Segment**: Revenue increased by 0.7% to $157.2 million, offsetting revenue lost from disposed assets [22] Market Data and Key Metrics Changes - The addressable markets within the four segments are growing in aggregate by mid-single digits, driven by an aging U.S. population and increasing prevalence of chronic conditions [8][6] - The company serves 4.2 million patients across over 660 locations in all 50 states, indicating a strong geographic footprint [8] Company Strategy and Development Direction - The company aims to deliver consistent, sustainable organic growth by focusing on its four core segments and enhancing patient service excellence [6][10] - There is a commitment to improving operational workflows and patient experience, particularly in the Diabetes Health segment [10][12] - The company is reducing debt and exiting non-core product lines to sharpen strategic focus [14][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to manage potential tariff impacts, indicating that current exposure is contained and manageable [15][16] - The company remains optimistic about the growth potential in the Diabetes Health segment and overall business despite current challenges [12][30] Other Important Information - The company has reduced its debt balance by $25 million in the first quarter, totaling $195 million over the last five quarters [13][24] - Full-year revenue expectations have been reduced by $40 million due to the sale of certain incontinence assets [25] Q&A Session Summary Question: Can you provide additional color on the improvement in the diabetes business? - Management noted positive movement in the pump business and sequential growth in new starts for continuous glucose monitors (CGMs) [28][29] Question: What is the situation with new starts in the sleep segment? - Management acknowledged a slight decline in new starts but emphasized confidence in addressing the issue through detailed plans [32][33] Question: Can you clarify the guidance changes related to asset sales? - The guidance change is exclusively for the incontinence asset sale, with no comments on the infusion asset sale until it is closed [29] Question: Are there opportunities for acquisitions in troubled markets? - Management confirmed ongoing M&A discussions and the potential for modest tuck-in acquisitions [60][59] Question: What is the company's exposure to tariffs for fiscal 2026? - Management indicated that they are feeling better about tariff exposure based on recent clarifications regarding product classifications [46][47] Question: How is the company positioned in the sleep market? - Management stated that improvements are needed in certain states to regain market share, with plans in place to address these challenges [54][55]